Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Dr. Irl B. Greenwell

Hematology Oncology | Hematology | Oncology
Bon Secours St Francis Xavier Hospital Inc
2085 Henry Tecklenburg Dr, 
Charleston, SC 
Accepting New Patients
Offers Telehealth
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Bon Secours St Francis Xavier Hospital Inc
2085 Henry Tecklenburg Dr, 
Charleston, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Irl Greenwell is a Hematologist Oncology specialist and a Hematologist in Charleston, South Carolina. Dr. Greenwell is rated as an Experienced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Sea-Blue Histiocytosis, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Greenwell is currently accepting new patients.

His clinical research consists of co-authoring 12 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in SC
Hospital Affiliations
Roper St Francis Hospital-Berkeley Inc
Roper Hospital
Mount Pleasant Hospital
Bon Secours-St Francis Xavier Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

BON SECOURS ST FRANCIS XAVIER HOSPITAL INC
2085 Henry Tecklenburg Dr, Charleston, SC 29414

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Ibrutinib
Study Phase: Phase 2
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
Enrollment Status: Suspended
Publish Date: September 10, 2025
Intervention Type: Drug
Study Drugs: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral Azacitidine
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
Enrollment Status: Terminated
Publish Date: February 04, 2025
Intervention Type: Other, Biological
Study Drug: AB-205
Study Phase: Phase 3
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Enrollment Status: Terminated
Publish Date: October 13, 2023
Intervention Type: Drug
Study Drug: Brentuximab
Study Phase: Phase 2
View 5 Less Clinical Trials

12 Total Publications

IKAROS gain of function disease: Allogeneic hematopoietic cell transplantation experience and expanded clinical phenotypes.
IKAROS gain of function disease: Allogeneic hematopoietic cell transplantation experience and expanded clinical phenotypes.
Journal: Clinical immunology (Orlando, Fla.)
Published: October 30, 2023
Similar Doctors
Advanced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Brian T. Hess
Hematology | Oncology | Hematology Oncology
Advanced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Brian T. Hess
Hematology | Oncology | Hematology Oncology

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (5.7 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Hess is a Hematologist and an Oncologist in Charleston, South Carolina. Dr. Hess is rated as an Elite provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Hess is currently accepting new patients.

Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Gary W. Thomas
Hematology Oncology | Hematology | Oncology
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Gary W. Thomas
Hematology Oncology | Hematology | Oncology

South Carolina Cancer Specialists

45 Hospital Ctr Cmns, 
Hilton Head Island, SC 
 (56.3 miles away)
843-689-2895
Languages Spoken:
English, Castilian, Spanish
See accepted insurances
Accepting New Patients

Gary Thomas is a Hematologist Oncology specialist and a Hematologist in Hilton Head Island, South Carolina. Dr. Thomas is rated as a Distinguished provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Mantle Cell Lymphoma (MCL), Paget Disease of the Breast, Richter Syndrome, and Chronic Lymphocytic Leukemia (CLL). Dr. Thomas is currently accepting new patients.

Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Ryan A. Kalinsky
Hematology Oncology | Hematology | Oncology
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Ryan A. Kalinsky
Hematology Oncology | Hematology | Oncology

Lowcountry Oncology Associates LLC

9313 Medical Plaza Dr, Suite 103, 
North Charleston, SC 
 (11.8 miles away)
843-790-8280
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ryan Kalinsky is a Hematologist Oncology specialist and a Hematologist in North Charleston, South Carolina. Dr. Kalinsky is rated as a Distinguished provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Familial Colorectal Cancer, and Appendix Cancer. Dr. Kalinsky is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Greenwell's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 16 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile